Kulkarni Law Firm
  • Our Team
  • Services
  • Blog
  • Contact
Select Page

Biosimilars: Unfairly Shortcutting the Approval Process?

by Sandy Buck | Jul 25, 2013 | Biologics, OGD, Safety

Introduction Biopharmaceuticals have demonstrated unparalleled advances for the treatment of cancer, immune diseases, and other common medical conditions, and are the fastest growing segment of the pharmaceutical industry today. Worldwide sales of these agents are...

TRICARE and Generic Prescription Drugs

by Christine Matusek | Apr 4, 2013 | Drugs, Financial Interest, OGD

Introduction TRICARE is the healthcare system employed by the Department of Defense (DoD) for use by the military. Healthcare, through TRICARE, is available to military service members (active duty, retired, and reserve) and dependents at almost no cost (dental...

Do People Favor Using Generic or Brand-Name Prescription Drugs?

by Fazal Chaudhry | Feb 20, 2013 | Drugs, OGD

Introduction With the growing cost of pharmaceuticals, people are turning toward generic drugs. Many people are making the necessary cutbacks in their lives to meet the higher cost of living. One of the cutbacks is switching from brand-name medicines to generic...

Are Generic Drugs as Safe and Effective as Brand-Name Drugs?

by Karan Sarna | Feb 7, 2013 | Drugs, OGD, Safety

Introduction For years, generic drugs have been taking over the pharmaceutical industry as the more cost-efficient option compared to brand names. Americans fill one billion prescriptions for generic medications yearly and rely on them to work just as well as brand...

Does the FDA Need to Strengthen its Standards on Generic Drugs?

by Oksana L | Jan 26, 2013 | Drugs, FDA, OGD

Introduction For many years the FDA, doctors, and pharmacists believed and encouraged consumers that generic drugs were indistinguishable to brand drugs. This belief allowed payers to refuse to pay for brand drugs. In various ways purchasing generic drugs seemed to be...

Patenting ETASU Programs to Delay Competition from Generic Drugs

by Denise Daley | Jan 8, 2013 | OGD, REMS

Introduction Innovator (brand-name) drug companies spend millions of dollars to develop a single, new innovator drug. It is therefore understandable that they would want competing drugs to remain off the market as long as possible. Many innovator drug companies have...

Recent Comments

  • admin on Pacira Lawsuit settled
  • Ray Powers on Pacira Lawsuit settled
  • KimK on Does Advertising of Commercially Available Regenerative Stem Cell Therapy Violate the Federal Trade Commission Act?
  • Christine Matusek on Generics vs. Brands: Who is to Blame When Something Goes Wrong?
  • Deepak on When to Submit as a Full Report, Abbreviated Report, or Synopsis

Newsletter

Blog Disclaimer

The opinions stated in this blog are the sole and present opinions of the blogger and do not necessarily represent the opinions of the Kulkarni Law Firm, PC and/or its attorneys. Such opinion(s) may change over time. Such opinion(s) should not necessarily be attributed to the institution for which these individuals may work or otherwise represent in any capacity. These blogs do not constitute legal advice and should not be construed as such.
  • Facebook
  • Twitter
  • Google
  • RSS
© 2015-2018 Kulkarni Law Firm